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Abstract
The use of human tissue, and material derived from such tissue, for research purposes is
currently the subject of much debate. This debate needs to address several issues,
including: the principle of abandonment; the distinction between identified and unidentified
specimens; general versus specific informed consent; and, with the improvement in
biotechnology and medical informatics, the design and security of research databases. The
outcome of this debate will shape the way in which research studies using human biological
materials are designed and executed.
Keywords: anonymized, coded, research, sample, tissue
Received: 8 February 2000
Revisions requested: 6 March 2000
Revisions received: 17 March 2000
Accepted: 23 March 2000
Published: 13 April 2000
Breast Cancer Res 2000, 2:237–240
The electronic version of this article can be found online at
http://breast-cancer-research.com/content/2/4/237
© Current Science Ltd
NBAC = National Bioethics Advisory Committee; OPRR = Office for Protection from Research Risks.
http://breast-cancer-research.com/content/2/4/237
Introduction
There is currently considerable debate regarding the
retention and use of human tissue for research purposes.
This debate has arisen partly because of the increase in
public concern about this issue, but also because of the
significant advances in both biotechnology and medical
informatics that have taken place in recent years. Thus,
potentially significant information regarding individuals is
being increasingly generated in research laboratories, and
these data are often stored on computerized databases
with varying degrees of security. These factors raise
issues of patient confidentiality, and the balance between
this confidentiality and the need for progress in biomedical
science must be carefully considered.
Principles
One of the fundamental issues in the retention of human
tissue for research purposes is the principle of abandon-
ment. Until recently, most biomedical researchers have
viewed excess tissue that has been removed for a diagnos-
tic or therapeutic procedure as ‘abandoned’, and therefore
such surplus material has been often used for research
purposes without specific patient consent. This approach
has recently been called into question [1,2], and it is likely
that informed consent will be required in the future for a
broader range of research involving human biological mate-
rial than has been the case thus far. This has significant
implications for research on human tissue and will necessi-
tate alterations in the way that routine consent is obtained
from patients. The central concept in this approach is that
patients are asked to ‘gift’ their tissue for research.
An important distinction when considering individual spec-
imens is whether they can be viewed as ‘identified’ or
‘unidentified’. Unidentified specimens, which can still be
associated with clinically relevant data, are either anony-
mous (ie no individual identifiers were recorded at the time
of collection) or anonymized (ie all specific patient identi-
fiers have been irreversibly removed from previously identi-
fied samples). The fundamental principle is that a link
cannot be made under any circumstances between the
specimen and the individual from whom the specimen was
obtained. Thus, there is no prospect of patient confiden-
tiality being breached. Conversely, identified specimensBreast Cancer Research    Vol 2 No 4 Prime et al
are associated with specific patient identifiers, and there-
fore can be linked to the patient of origin.
Between these two extremes, there are coded or linked
specimens. For these, the specific patient identifiers are
separated from the other information about the specimen,
as well as research data derived from the specimen, such
that no immediate link can be made with the patient.
However, a mechanism still exists, through the use of
coding systems, by which the patient can be identified.
Many tissue collections fall into the category of coded/
linked samples, and it is this category that is currently
causing concern.
Where the specimen is specifically identified, specific
informed consent must be obtained. Where the specimen
is anonymous or anonymized there is usually no issue of
confidentiality, but there is also no possibility of obtaining
further information about the patient, particularly clinical
follow-up data. This may significantly reduce the research
value of the specimen. Coded or linked specimens
provide the opportunity to protect patient confidentiality
while maintaining a possible link such that clinical follow-
up information can be obtained. One way of achieving this
is to introduce a firewall between the specific patient iden-
tifiers and the rest of the clinical and biological informa-
tion. The use of encryption techniques has been
suggested for this purpose. A further complication is the
realization that, on rare occasions, especially with very
small sample populations, an accumulation of nonspecific
identifiers may theoretically lead to identification of an indi-
vidual through an otherwise ‘anonymized’ sample that has
no associated name or chart number [2]. This is an impor-
tant consideration when designing databases.
The issue of consent is intimately involved with the types
of samples that may be used in a research study. Clearly,
if the principle of abandonment is rejected, the logical con-
sequence is that consent will be required in most cases
when human biological materials are to be used for
research purposes, and not necessarily only for identified
or coded samples. At the very least, use of identified
samples will require informed consent, involving providing
the patient with sufficient information to make an informed
decision regarding whether to participate in a particular
research project.
A distinction can be made between general versus spe-
cific informed consent. With the former, patients give
blanket or unspecified consent to use their material for
research purposes without identification of a specific
project. The validity of blanket or general consent has
recently been questioned [2]. Specific informed consent,
on the other hand, governs the situation in which consent
is provided for a specific project with known risks and
benefits. However, it is clearly not always possible to
anticipate potential research projects or technical
advances that might make more sophisticated investiga-
tion possible in the future. It has been suggested [2] that
when a clinical sample is obtained, the patient’s willing-
ness to be recontacted in the future for a possible
research study should be determined. Clearly, this has
time and cost implications and may limit the availability of
samples for future studies. For both forms of consent,
there is a need to consider the detail with which consent
is obtained, for example with regard to custodianship of
tissue and issues of commercialization. The more detailed
and unwieldy consent forms become, the less likely
patients will be to give their consent, thereby potentially
inhibiting research activity. Conversely, care must be taken
to ensure that sufficient information is provided for
consent to be ‘informed’.
Agreement by a patient to participate in a research study
should not be linked to availability of clinical care. Partici-
pation in research should be voluntary and not coerced. It
is also important to note that internationally agreed princi-
ples of human subjects research state that consent is not
irreversible. Thus, it should be made clear to patients that
they have the right to opt out of a study and remove their
samples at any time.
Another important issue to be considered is the nature of
the information that is to be derived from the research activ-
ity. Although many groups have stressed that all biomedical
research is potentially sensitive [3], some people are partic-
ularly concerned about the generation of genetic informa-
tion [1,2], which may have implications for propensity of
disease development, not only for the patient, but also for
the patient’s family. This is particularly relevant in cancer
research, where an individual gene mutation or polymor-
phism may be associated with elevation or reduction in the
risk of developing a particular tumour or group of tumours.
Furthermore, the issue of whether patients should be
informed of the results of research investigations is not a
simple one. For example, it is important that research data
are reliable, valid and relevant to the disease process. In
the USA, it has been suggested that before being used to
make clinical decisions, genetic information generated in
research studies should be independently validated by
accredited laboratories. However, this may not be possible
during test development of rare disorders. Again, this issue
represents a balance between the harm that could be done
to individuals if confidentiality is violated on the one hand,
and on the other the potential impairment of generation of
new knowledge if overly stringent measures are taken to
protect patient confidentiality that result in an inability to
conduct the research study at all. Careful attention to confi-
dentiality and privacy policies, and the security of research
data, should be a hallmark of all research on human biologi-
cal materials to prevent misuse of research information.http://breast-cancer-research.com/content/2/4/237
Current status
UK
Several government and professional bodies have recently
considered the issue of using human biological materials
in research [4–7]. The Medical Research Council [4] has
published interim operational and ethical guidelines for the
use of human tissue and biological samples in research,
including their use by commercial companies. These
guidelines explore many of the issues touched on above
and, in particular, put forward the suggestion that the prin-
ciple of abandonment is no longer valid.
Thus, in the UK it is likely that ethical approval and specific
patient consent will be required for the use of biological
materials in research. This specifically includes archival
material in pathology departments that, traditionally, has
not required such approval and consent. Although it is
suggested that this should not operate in retrospect, in
view of the tremendous difficulties there would be in
obtaining patient consent for material currently being
stored in tissue archives, it does mean that hospital
consent forms will have to be altered in order to obtain
informed consent from all patients undergoing interven-
tional or operative procedures. Moreover, it is recom-
mended that such consent be obtained separately from
the consent to operation so that it is clear to patients what
is being asked of them. The principle of informed consent
also requires that patients be given sufficient information
to make an informed decision and also be given sufficient
time to assimilate this information. This has significant
implications for the time that will need to be invested in
obtaining patient consent, and therefore for manpower.
The design and funding of research will therefore need to
take these issues into account.
USA
In the USA, federally funded research involving human
subjects (including the use of their tissues) is overseen by
the Office for Protection from Research Risks (OPRR).
Nonfederally funded research is not regulated in the USA
except at the local level, although research conducted in
institutions that accept federal funds, even when not
specifically federally funded, is usually subject to federal
regulations by agreements between the OPRR and the
medical institutions. For the most part, research con-
ducted on excess human biological materials has been
covered by a general statement within the clinical consent
form that permits use of such samples for research and
education. Also, in practice many biomedical researchers
have not appreciated that the informed consent require-
ment applies to their work on coded human samples.
Recently, President Clinton’s National Bioethics Advisory
Commission (NBAC) released a report [2] recommending
guidelines for the use of human biological materials in
research. To a large extent, the NBAC supports the current
OPRR interpretation of regulations, including the consider-
ation of coded samples as identified. Therefore, research
utilizing coded human biological materials requires
informed consent and review by a local institutional review
board. The board can waive the informed consent require-
ment under specific circumstances that include assess-
ment of minimal risk to the patient, of patient personal
autonomy, and of the practicability of obtaining consent (eg
for use of archived samples). Unidentified samples (eg
anonymous and anonymized samples) are exempt from the
regulations, as are samples from patients who are no
longer living. The NBAC report [2] recommended that the
exemption of samples from deceased individuals be recon-
sidered, and also strongly urged an improved consent
process, including separation of consent for research from
consent for the clinical procedure.
The National Action Plan for Breast Cancer recently for-
mulated new consent forms and procedures [8], and
these are under investigation for feasibility. Although the
NBAC recommendations do not have legal standing, it is
generally presumed that institutional review boards and
regulators will use them as a guide pending further legisla-
tive changes. There is no doubt, however, that the new
sensitivity to the use of coded samples and the conse-
quent requirement for informed consent will impact on the
design and execution of research studies using human
biological materials.
Conclusion
In conclusion, the debate regarding the use of human
tissue for research purposes needs to address several
issues, including: the principle of abandonment; the dis-
tinction between identified and unidentified specimens;
general versus specific informed consent; and, with the
improvement in biotechnology and medical informatics,
the design and security of research databases. The
outcome of this debate will shape the way in which
research studies using human biological materials are
designed and executed.
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